Horizon Discovery Group Plc (LON:HZD) price target maintained at 194.00GBX, reported earlier today by N+1 Singer
- Updated: September 19, 2016
In a report released on 9/20/2016 N+1 Singer held steady the target price of Horizon Discovery Group Plc (LON:HZD) at 194GBX reporting a possible upside of 0.27%.
Yesterday Horizon Discovery Group Plc (LON:HZD) traded 7.03% lower at 152.50GBX. HZD’s 50-day moving average is 160.39GBX and its two hundred day moving average is 160.58GBX. The last stock price is down 4.47% relative to the 200-day moving average, compared to the S&P 500 which has fallen -0.01% over the date range. Trade volume was up over the average, with 967,951 shares of HZD changing hands over the typical 160,373 shares..
Recent Performance Graph:
With a total market value of 0.0 GBX, Horizon Discovery Group Plc has a price-earnings of 0 with a 52 week low of 125.00GBX and a 52 week high of 188.06GBX.
In addition to N+1 Singer reporting it’s stock price target, a total of 3 firms have reported on Horizon Discovery Group Plc. The average target price is 218.67GBX with one firm rating the company a strong buy, two analysts rating the company a buy, one firm rating the stock a hold, 0 rating the stock to underperform, and lastly 0 firmsrating the company as sell.
Brief Synopsis About Horizon Discovery Group Plc (LON:HZD)
Horizon Discovery Group PLC is a gene editing company that designs and engineers genetically-modified cells, applying them in research and clinical applications to advance human health. The Company’s gene editing platform, able to alter almost any gene sequence, has generated a catalogue of over 23, 000 cell and in vivo models that recapitulate the genetic anomalies found in diseases like cancer. These models have been adopted by c1, 400 organizations to better understand of the genetic drivers of disease, and by Horizon in a range of services offered to customers, and as well as in the Company’s own research R&D pipeline.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.